Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
Arcutis Biotherapeutics announced changes to its board leadership and a new consulting role for a retiring director. Bhaskar Chaudhuri retired from the board and as chair of the Compensation Committee on December 3, 2025, and entered into a transition and consulting agreement under which he will hold the honorary title of Founder and Director Emeritus and provide strategic advisory support through June 30, 2027. During this period, his existing stock options and restricted stock units will continue to vest, and he may exercise vested options, with a three-month post-termination exercise window.
On December 4, 2025, the board appointed Amit D. Munshi as a new Class II director and chair of the Compensation Committee, with a term running until the 2028 annual meeting of stockholders, subject to earlier departure events. As a non-employee director, he received an initial stock option grant for 16,502 shares of common stock and is eligible for a prorated annual equity award valued at approximately $300,000, allocated 65% to stock options and 35% to restricted stock units, plus prorated annual cash retainers of $50,000 for board service and $15,000 for chairing the Compensation Committee.
Arcutis Biotherapeutics (ARQT) director Sue-Jean Lin reported stock option exercises and a share sale. On 11/24/2025, Lin exercised options to acquire 18,052 shares of common stock at an exercise price of $8.63 per share and another 7,220 shares at $7.51 per share. That same day, Lin sold 25,272 shares of common stock at a weighted average price of $30.7833 per share, in multiple trades between $30.56 and $30.91. After these transactions, Lin directly beneficially owned 26,735 shares of Arcutis common stock, along with remaining stock options for 9,000 shares and 5,000 shares that are exercisable into common stock.
Arcutis Biotherapeutics (ARQT) insider Todd Franklin Watanabe, the company’s President, Chief Executive Officer and a director, reported open-market sales of common stock on a Form 4. On November 21, 2025, he sold 1,055 shares of common stock at a price of $30.00 per share. On November 24, 2025, he sold an additional 48,945 shares at a weighted average price of $30.3556 per share.
The filing states these transactions were made under a Rule 10b5-1 trading plan adopted on June 3, 2025, with a plan end date of September 30, 2026. Following the reported sales, Watanabe beneficially owns 740,537 shares of Arcutis common stock directly, plus additional indirect holdings through several trusts and an LLC, for which he disclaims full beneficial ownership except to the extent of his economic interest.
Arcutis Biotherapeutics (ARQT) executive Masaru Matsuda, an officer serving as SVP General Counsel and Corporate Secretary, reported sales of company stock in a Form 4 filing. On 11/19/2025, he sold 989 shares of common stock at a weighted average price of $27.9541 and 1,561 shares at a weighted average price of $28.5. The sales were made to cover tax withholding obligations related to the vesting of Restricted Stock Units, rather than as discretionary open-market sales. After these transactions, Matsuda beneficially owned 151,476 shares of Arcutis common stock, held directly.
Arcutis Biotherapeutics (ARQT) director Halley E. Gilbert reported an option exercise and share sale. On 11/20/2025, Gilbert exercised a stock option to buy 12,220 shares of common stock at an exercise price of $7.51 per share. The underlying option had vested 100% on the first anniversary of May 31, 2023, subject to continuous service as a non-employee director.
On the same date, Gilbert sold 16,532 shares of common stock in open-market transactions at a weighted average price of $27.5491 per share, with individual trades ranging from $27.32 to $27.72. Following these transactions, Gilbert directly beneficially owned 22,123 shares of Arcutis Biotherapeutics common stock, and held no remaining derivative securities from this reported option.
Arcutis Biotherapeutics (ARQT) director Neha Krishnamohan reported option exercises and share sales. On 11/13/2025, she exercised stock options to acquire 27,052 shares at $8.63 and 12,220 shares at $7.51 per share, then sold 39,272 shares at a weighted average price of $23.1896 and an additional 1,232 shares at $23.37.
After these transactions, she directly owned 22,123 shares of Arcutis common stock. The filing notes that these trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025, with an end date of November 2, 2026, which is designed to allow insiders to sell shares according to a preset schedule.
Arcutis Biotherapeutics, Inc. (ARQT) director Keith Leonard reported a charitable gift of company stock. On 11/13/2025, he transferred 4,312 shares of Arcutis common stock in a transaction coded as a gift at a stated price of $0, described as a transfer to a Charitable Remainder Unitrust. After this transaction, he reported owning 22,123 shares directly. He also reported 1,750 shares held indirectly through the Leonard Family Trust dated August 28, 1996, for which he serves as a trustee and disclaims beneficial ownership beyond his pecuniary interest.
Arcutis Biotherapeutics (ARQT): Reporting person Larry Todd Edwards, EVP Chief Commercial Officer, reported an open-market sale of 29,131 shares of common stock on 11/06/2025 at a weighted average price of $25.1597. The filing notes multiple trades within a $25.00–$25.2600 range.
Following the transaction, the reporting person beneficially owns 150,193 shares, held directly. The filer undertakes to provide detailed trade-by-trade information upon request, as customary for weighted-average disclosures.
Arcutis Biotherapeutics (ARQT) insider transaction: On 11/06/2025, the company’s Executive Vice President and Chief Medical Officer exercised stock options for 17,250 shares at $3.64 and sold 17,250 common shares at a weighted average price of $24.1823, with trades executed between $23.79 and $24.4493. The transactions were effected under a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026.
Following these transactions, the reporting person beneficially owned 98,325 shares of common stock and 155,250 derivative securities (options). The reported option grant vests monthly over four years from January 12, 2024, until fully vested on the fourth anniversary.
Arcutis Biotherapeutics (ARQT) filed a Form 4 reporting insider stock sales. Executive Vice President and Chief Medical Officer Patrick Burnett reported selling 2,607 shares of common stock on 11/03/2025 at a weighted average price of $24.7124 and 15 shares at $25.4. He also sold 3,864 shares on 11/05/2025 at a weighted average price of $23.7172. Following these transactions, he beneficially owned 98,325 shares directly.
The 11/03/2025 sale was made to cover tax withholding obligations tied to vesting Restricted Stock Units. The 11/05/2025 transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026.